Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.

about

CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation.

P2860

Q41076029-89869EA9-D348-4747-B0C8-9846F71CBB7F

P2860

Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q38983980

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Chemotherapy and intercalated ...... ed non-small-cell lung cancer.

@en

type

Item

label

Chemotherapy and intercalated ...... ed non-small-cell lung cancer.

@en

prefLabel

Chemotherapy and intercalated ...... ed non-small-cell lung cancer.

@en

P1476

Chemotherapy and intercalated ...... ed non-small-cell lung cancer.

@en

P2093

Anna La Salvia

http://www.w3.org/2001/XMLSchema#string

Antonio Rossi

http://www.w3.org/2001/XMLSchema#string

Massimo Di Maio

http://www.w3.org/2001/XMLSchema#string

P2860

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Erlotinib in previously treated non-small-cell lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

P304

171-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17476348.2017.1290526

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28152323

http://www.w3.org/2001/XMLSchema#string

Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.

about

P2860

P2860

Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698